Compare BMBL & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BMBL | DSGN |
|---|---|---|
| Founded | 2014 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 783.9M | 853.8M |
| IPO Year | 2021 | 2021 |
| Metric | BMBL | DSGN |
|---|---|---|
| Price | $6.00 | $10.81 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 9 | 8 |
| Target Price | $4.21 | ★ $21.57 |
| AVG Volume (30 Days) | ★ 11.7M | 416.0K |
| Earning Date | 11-09-2026 | 11-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $965,658,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.44 | $6.81 |
| 52 Week High | $6.00 | $17.25 |
| Indicator | BMBL | DSGN |
|---|---|---|
| Relative Strength Index (RSI) | 87.42 | 47.71 |
| Support Level | $2.62 | $9.83 |
| Resistance Level | $6.00 | $11.43 |
| Average True Range (ATR) | 0.03 | 0.61 |
| MACD | -0.10 | 0.08 |
| Stochastic Oscillator | 92.86 | 60.94 |
Bumble Inc is engaged in offering online dating services. The platform enables people to connect and build healthy and equitable relationships on their own terms. The company operates two apps, Bumble and Badoo, where users come every month to discover new people and connect. The company operates as one operating segment with revenue derived in the form of recurring subscriptions and in-app purchases. The company operates in USA, which derives maximum revenue; and Rest of the World.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the research and development of GeneTAC molecules, which are a novel class of small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its pipeline includes Friedreich Ataxia, FECD, DM1, and Huntington's Disease. The company operates in one operating and reportable segment focused on utilizing the company's proprietary GeneTAC platform to design and develop therapeutic candidates for inherited diseases driven by nucleotide repeat expansion.